| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-05-03 | Abbott (USA) Action Pharma (Denmark) | AP214 | prevent acute kidney injury associated with major cardiac surgery and other relevant indications | licensing |
Kidney diseases - Renal diseases | Licensing agreement |
| 2012-05-03 | Quark Pharmaceuticals (USA) Pfizer (USA - NY) Silence Pharmaceuticals (UK) | PF-655 (synthetic siRNA) | moderate and advanced open-angle glaucoma | licensing |
Ophtalmological diseases | Licensing agreement |
| 2012-05-02 | Evotec (Germany) Conba Pharmaceutical (China) | EVT401 | inflammatory diseases | development |
Inflammatory diseases | Development agreement |
| 2012-05-02 | Gentium (Italy) PharmaSwiss, (Switzerland), a division of Valeant Pharmaceuticals International (Canada) | defibrotide | prevention and treatment of hepatic veno-occlusive disease (VOD) |
distribution |
Digestive diseases - Liver diseases - Transplantation | Distribution agreement |
| 2012-05-02 | Nanobiotix (France) Thomas Jefferson University (USA) | NBTXR3 | cancer | development |
Cancer - Oncology | Development agreement |
| 2012-05-01 | GSK (UK) Yale University (USA) | medicines that degrade disease-causing proteins | R&D |
Cancer Oncology - Infectious diseases - Inflammatory diseases | R&D agreement | |
| 2012-05-01 | Dako (Denmark) Genentech a member of the Roche Group (USA-Switzerland) | HercepTest™ and HER2 FISH pharmDx™ as companion diagnostics for trastuzumab emtansine (T-DM1) | advanced HER2-positive breast cancer | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2012-04-30 | Sanofi (France) Algeta (Norway) | thorium-conjugated tumor-targeting antibody (TTC) | tumors | R&D |
Cancer - Oncology | R&D agreement |
| 2012-04-30 | H3 Biomedicine (USA) Horizon Discovery (UK) | novel cancer targets | various cancers | R&D |
Cancer - Oncology | R&D agreement |
| 2012-04-26 | MDxHealth (Belgium) PLUS Diagnostics (USA) | ConfirmMDx™ for Prostate Cancer | prostate cancer | co-promotion |
Cancer - Oncology | Commercialisation agreement |
| 2012-04-26 | Evotec (Germany) Active Biotech (Sweden) | novel small molecule modulators of a priority biological target involved in immune disorders and cancer | cancers, immune diseases | collaboration |
Cancer - Oncology - Immune diseases | R&D agreement |
| 2012-04-26 | BioAlliance Pharma (France) Herlev Hospital of Copenhagen (Denmark) | Amep® (targeted biotherapy) | collaboration |
Clinical research agreement | ||
| 2012-04-25 | AstraZeneca (UK) The Medicines Company (USA) | Brilinta® (ticagrelor) - Angiomax® (bivalirudin) for injection - cangrelor | acute ischaemic heart disease, acute coronary syndrome | development |
Cardiovascular diseases | Development agreement |
| 2012-04-24 | Novo Nordisk (Denmark) Oxford University (UK) | novel treatments and biomarkers for rheumatoid arthritis and other inflammatory diseases | rheumatoid arthritis and other inflammatory diseases | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | R&D agreement | |
| 2012-04-23 | Alnylam Pharmaceuticals (USA - MA) Plant Bioscience Limited (UK) | Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics | licensing |
Licensing agreement | ||
| 2012-04-23 | Abcodia (UK) Biouniversa (Italy) | BAG3 protein biomarker | pancreatic cancer | development |
Cancer - Oncology | Development agreement |
| 2012-04-19 | Sanofi (France) The Michael J. Fox Foundation (USA) | AVE 8112 | Parkinson’s disease | collaboration |
Neurodegenerative diseases - CNS diseases | Clinical research agreement |
| 2012-04-19 | Iris Pharma (France) RxGen (USA) | “bench-to-bedside” ophthalmology research services | collaboration |
Ophtalmological diseases | Collaboration agreement | |
| 2012-04-18 | Lonza (Switzerland) CSIRO (Australia) | new insect silk based products | development |
Development agreement | ||
| 2012-04-18 | Selcia (UK) Heptares Therapeutics (UK) | fragment ligands that specifically bind to a Family B stabilised GPCR (StaR®) drug target purified by Heptares | collaboration |
Collaboration agreement |
